Literature DB >> 28144911

Pharmacokinetic Steady-States Highlight Interesting Target-Mediated Disposition Properties.

Johan Gabrielsson1, Lambertus A Peletier2.   

Abstract

In this paper, we derive explicit expressions for the concentrations of ligand L, target R and ligand-target complex RL at steady state for the classical model describing target-mediated drug disposition, in the presence of a constant-rate infusion of ligand. We demonstrate that graphing the steady-state values of ligand, target and ligand-target complex, we obtain striking and often singular patterns, which yield a great deal of insight and understanding about the underlying processes. Deriving explicit expressions for the dependence of L, R and RL on the infusion rate, and displaying graphs of the relations between L, R and RL, we give qualitative and quantitive information for the experimentalist about the processes involved. Understanding target turnover is pivotal for optimising these processes when target-mediated drug disposition (TMDD) prevails. By a combination of mathematical analysis and simulations, we also show that the evolution of the three concentration profiles towards their respective steady-states can be quite complex, especially for lower infusion rates. We also show how parameter estimates obtained from iv bolus studies can be used to derive steady-state concentrations of ligand, target and complex. The latter may serve as a template for future experimental designs.

Keywords:  constant-rate infusion protocol; drug disposition; drug-target interaction

Mesh:

Year:  2017        PMID: 28144911     DOI: 10.1208/s12248-016-0031-y

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  17 in total

1.  General pharmacokinetic model for drugs exhibiting target-mediated drug disposition.

Authors:  D E Mager; W J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-12       Impact factor: 2.745

2.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

Review 3.  Antibody pharmacokinetics and pharmacodynamics.

Authors:  Evelyn D Lobo; Ryan J Hansen; Joseph P Balthasar
Journal:  J Pharm Sci       Date:  2004-11       Impact factor: 3.534

4.  Simple model to explain effects of plasma protein binding and tissue binding on calculated volumes of distribution, apparent elimination rate constants and clearances.

Authors:  J G Wagner
Journal:  Eur J Clin Pharmacol       Date:  1976       Impact factor: 2.953

5.  Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis.

Authors:  R J Bauer; R L Dedrick; M L White; M J Murray; M R Garovoy
Journal:  J Pharmacokinet Biopharm       Date:  1999-08

6.  Clearance concepts in pharmacokinetics.

Authors:  M Rowland; L Z Benet; G G Graham
Journal:  J Pharmacokinet Biopharm       Date:  1973-04

Review 7.  Pharmacologic target-mediated drug disposition.

Authors:  G Levy
Journal:  Clin Pharmacol Ther       Date:  1994-09       Impact factor: 6.875

Review 8.  Clearance (née Rowland) concepts: a downdate and an update.

Authors:  Leslie Z Benet
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-11-27       Impact factor: 2.745

9.  Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification.

Authors:  Lambertus A Peletier; Johan Gabrielsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-08-01       Impact factor: 2.745

Review 10.  Cell surface receptors for signal transduction and ligand transport: a design principles study.

Authors:  Harish Shankaran; Haluk Resat; H Steven Wiley
Journal:  PLoS Comput Biol       Date:  2007-04-20       Impact factor: 4.475

View more
  9 in total

1.  Guiding dose selection of monoclonal antibodies using a new parameter (AFTIR) for characterizing ligand binding systems.

Authors:  Sameed Ahmed; Miandra Ellis; Hongshan Li; Luca Pallucchini; Andrew M Stein
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-04-29       Impact factor: 2.745

2.  The computation of biomarkers in pharmacokinetics with the aid of singular perturbation methods.

Authors:  Jie Ma; James P Keener
Journal:  J Math Biol       Date:  2018-07-28       Impact factor: 2.259

3.  Michaelis-Menten from an In Vivo Perspective: Open Versus Closed Systems.

Authors:  Johan Gabrielsson; Lambertus A Peletier
Journal:  AAPS J       Date:  2018-09-12       Impact factor: 4.009

4.  Impact of target interactions on small-molecule drug disposition: an overlooked area.

Authors:  Robert A B van Waterschoot; Neil J Parrott; Andrés Olivares-Morales; Thierry Lavé; Malcolm Rowland; Dennis A Smith
Journal:  Nat Rev Drug Discov       Date:  2018-02-23       Impact factor: 84.694

5.  New Equilibrium Models of Drug-Receptor Interactions Derived from Target-Mediated Drug Disposition.

Authors:  Lambertus A Peletier; Johan Gabrielsson
Journal:  AAPS J       Date:  2018-05-14       Impact factor: 4.009

6.  Challenge model of TNFα turnover at varying LPS and drug provocations.

Authors:  Felix Held; Edmund Hoppe; Marija Cvijovic; Mats Jirstrand; Johan Gabrielsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-02-18       Impact factor: 2.745

7.  Does In Vitro Potency Predict Clinically Efficacious Concentrations?

Authors:  Rasmus Jansson-Löfmark; Stephan Hjorth; Johan Gabrielsson
Journal:  Clin Pharmacol Ther       Date:  2020-05-10       Impact factor: 6.875

8.  Impact of mathematical pharmacology on practice and theory: four case studies.

Authors:  Lambertus A Peletier; Johan Gabrielsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-09-07       Impact factor: 2.745

Review 9.  Interpretation of Drug Interaction Using Systemic and Local Tissue Exposure Changes.

Authors:  Young Hee Choi
Journal:  Pharmaceutics       Date:  2020-05-02       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.